Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

21.97 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Expert Ratings For ACADIA Pharmaceuticals ↗

February 09, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Acadia: Helping With Alzheimers And Parkinsons ↗

April 03, 2022

Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia...

Via Talk Markets

Stocks And Oil Drop Following The Weak Job Report ↗

March 30, 2022

It was a strange day for the market that started with a big miss on the ADP job report.

Via Talk Markets

9 Monster Stock Market Predictions For The Week Of March 28 ↗

March 27, 2022

It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the...

Via Talk Markets

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

March 22, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today ↗

March 16, 2022

We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about!

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗

March 16, 2022

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...

Via Benzinga

A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision ↗

March 16, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results...

Via Benzinga

Expert Ratings For ACADIA Pharmaceuticals ↗

March 03, 2022

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks...

Via Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings ↗

February 28, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis ↗

February 16, 2022

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated...

Via Benzinga

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

February 16, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

February 14, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

February 11, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗

February 09, 2022

Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment...

Via Benzinga

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders ↗

January 10, 2022

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of...

Via Benzinga

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

January 10, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗

January 05, 2022

Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:

Via Benzinga

What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

January 05, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:

Via Benzinga

$1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much ↗

December 28, 2021

ACADIA Pharmaceuticals (NASDAQ:ACAD) has outperformed the market over the past 10 years by 22.05% on an annualized basis. Buying $1,000 In ACAD: 10 years ago, an investor could...

Via Benzinga

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 ↗

December 27, 2021

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 23, 2021

Gainers Tempest Therapeutics (NASDAQ:TPST...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.